Table 5.
Variables | S-IPSS Score | Allele Positivity Odds Ratio (95% Confidence Interval) |
V-IPSS | Allele Positivity Odds Ratio (95% Confidence Interval) |
|||
---|---|---|---|---|---|---|---|
Mild/ Moderate <20, n (%) |
Severe ≥20, n (%) |
Mild/ Moderate <20, n (%) |
Severe ≥20, n (%) |
||||
Gender | Male | 36 (78.3) | 10 (21.7) | 2.29 (0.94–5.57); p = 0.065 | 38 (82.6) | 8 (17.4) | 0.28 (0.07–1.12); p = 0.059 |
Female | 33 (61.1) | 21 (38.9) | 51 (94.4) | 3 (5.6) | |||
rs2052129 (c.691G>T) |
GG | 29 (74.4) | 10 (25.6) | 1.52 (0.62–3.71); p = 0.354 | 39 (100.0) | 0 | 17.0 (1.03–314.7); p = 0.006 * |
GT-TT | 40 (65.6) | 21 (34.4) | 50 (82.0) | 11 (18.0) | |||
rs10156191 (p.Thr16Met) |
CC | 26 (76.5) | 8 (23.5) | 1.74 (0.68–4.45); p = 0.246 | 34 (100.0) | 0 | 14.3 (0.82–250.4); p = 0.014 * |
CT-TT | 43 (65.2) | 23 (34.8) | 55 (83.3) | 11 (16.7) | |||
rs1049742 (p.Ser332Phe) |
CC | 38 (71.7) | 15 (28.3) | 1.31 (0.56–3.06); p = 0.536 | 50 (94.3) | 3 (5.7) | 3.42 (0.85–13.75); p = 0.070 |
CT-TT | 31 (66.0) | 16 (34.0) | 39 (83.0) | 8 (17.0) | |||
rs1049743 (p.His664Asp) |
CC | 26 (63.4) | 15 (36.6) | 0.64 (0.27–1.52); p = 0.314 | 38 (92.7) | 3 (7.3) | 1.99 (0.49–7.99); p = 0.518 |
CG-GG | 43 (72.9) | 16 (27.1) | 51 (86.4) | 3 (16.3) | |||
rs2052129 rs10156191 |
No | 31 (73.8) | 11 (26.2) | 1.48 (0.62–3.56); p = 0.376 | 42 (100.0) | 0 | 20.58 (1.86–359.9); p = 0.002 * |
Yes | 38 (65.5) | 20 (34.5) | 47 (81.0) | 11 (19.0) | |||
SNPs | < 4 SNPs | 50 (72.5) | 19 (27.5) | 1.66 (0.68–4.07); p = 0.264 | 65 (94.2) | 4 (5.8) | 4.74 (1.27–17.65); p = 0.032 |
4 SNPs | 19 (61.3) | 12 (38.7) | 15 (48.4) | 16 (51.6) | |||
Homozygosity | No | 61 (70.1) | 26 (29.9) | 1.47 (0.44–4.90); p = 0.534 | 80 (92.0) | 7 (8.0) | 5.08 (1.24–20.77); p = 0.035 |
Yes | 8 (61.5) | 5 (38.5) | 9 (69.2) | 4 (30.8) |
S-IPSS: storage subscale of the International Prostate Symptom Score; V-IPSS: voiding subscale of the International Prostate Symptom Score; * Estimated odds ratio with the Haldane–Anscombe correction or Fisher’s exact test.